Literature DB >> 12113133

Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century.

M Raderer1, P G Isaacson.   

Abstract

Extranodal lymphomas arising from mucosa associated lymphoid tissue (MALT) have become a focus of interest in recent years due to their unique pathological and clinical properties. The link between Helicobacter pylori and the development of gastric MALT-type lymphoma has revolutionized treatment options as up to 80% of patients with early gastric MALT-type lymphoma achieve complete remission of the tumor following eradication of H. pylori. As opposed to surgical intervention, which has been the preferred form of treatment in the past, organ conserving approaches are increasingly being applied, as both irradiation and chemotherapy have given excellent results. However, mature data from prospective, randomized studies taking into account the concept of MALT lymphoma as a distinct entity are still lacking in order to define the optimal approach to the management of MALT-type lymphoma.

Entities:  

Mesh:

Year:  2001        PMID: 12113133     DOI: 10.1586/14737140.1.1.53

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  3 in total

1.  Primary extranodal lymphomas of gastrointestinal localizations: a single institution 5-yr experience.

Authors:  B Mihaljević; R Nedeljkov-Jancić; V Vujicić; D Antić; S Janković; N Colović
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas.

Authors:  M Raderer; B Streubel; S Wöhrer; M Häfner; A Chott
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

3.  A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma.

Authors:  Werner Dolak; Barbara Kiesewetter; Leonhard Müllauer; Marius Mayerhoefer; Marlene Troch; Michael Trauner; Michael Häfner; Markus Raderer; Andreas Püspök
Journal:  Surg Endosc       Date:  2015-10-20       Impact factor: 4.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.